Neuropeptide Y attenuates stress-induced bone loss through suppression of noradrenaline circuits

Journal of Bone and Mineral Research

Volumn 29, Issue 10, 2014, Pages 2238-2249

  Baldock, P A ^a,b   Lin, S ^a   Zhang, L ^a   Karl, T ^a,b   Shi, Y ^a   Driessler, F ^a   Zengin, A ^a   Hormer B ^a   Lee, N J ^a   Wong, I P L ^a   Lin, E J D ^a   Enriquez, R F ^a   Stehrer, B ^a   During, M J ^c   Yulyaningsih, E ^a   Zolotukhin, S ^d   Ruohonen, S T ^e   Savontaus, E ^e   Sainsbury, A ^a,b   Herzog, H ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Bone Histomorphometry; Bone QCT CT; Bone brain nervous System Interactions; Genetic Animal Models; Neuroendocrine

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE Y; NORADRENALIN; NEUROPEPTIDE Y RECEPTOR; PROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARCUATE NUCLEUS; ARTICLE; CATECHOLAMINERGIC SYSTEM; CELL ACTIVITY; COLD STRESS; MOUSE; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC NERVE; OSTEOBLAST; OSTEOLYSIS; PARAVENTRICULAR THALAMIC NUCLEUS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE CELL; ANIMAL; ANTIBODY SPECIFICITY; ANXIETY; BIOLOGICAL MODEL; BLOOD; COMPLICATION; ETIOLOGY; MENTAL STRESS; METABOLISM; NERVE CELL;

ANIMALS; ANXIETY; ARCUATE NUCLEUS OF HYPOTHALAMUS; BEHAVIOR, ANIMAL; BONE RESORPTION; MICE; MODELS, BIOLOGICAL; NEURONS; NEUROPEPTIDE Y; NOREPINEPHRINE; ORGAN SPECIFICITY; PROTECTIVE AGENTS; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 84907654878     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2205     Document Type: Article

References (55)

1. Liu RT, Alloy LB. Stress generation in depression: a systematic review of the empirical literature and recommendations for future study. Clin Psychol Rev. 2010;30(5):582-93.
2. Marcovecchio ML, Chiarelli F. The effects of acute and chronic stress on diabetes control. Sci Signal.2012 Oct 23;5(247): pt 10.
3. Golovatscka V, Ennes H, Mayer EA, Bradesi S. Chronic stress-induced changes in pro-inflammatory cytokines and spinal glia markers in the rat: a time course study. Neuroimmunomodulation. 2012;19(6):367-76.
4. Devaki M, Nirupama R, Yajurvedi HN. Chronic stress-induced oxidative damage and hyperlipidemia are accompanied by atherosclerotic development in rats. Stress. 2013 Mar;16(2):233-43.
5. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007;6(4):430-3.
6. Alberini CM. Unwind: chronic stress exacerbates the deficits of Alzheimer's disease. Biol Psychiatry. 2009;65(11):916-7.
7. Cizza G, Primma S, Coyle M, Gourgiotis L, Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42(7):467-82.
8. Wu Q, Magnus JH, Liu J, Bencaz AF, Hentz JG. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos Int. 2009;20(8):1309-20.
9. Yirmiya R, Bab I. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry. 2009;66(5):423-32.
10. Cizza G, Ravn P, Chrousos GP, Gold PW. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab. 2001;12(5):198-203.
11. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335(16):1176-81.
12. Dorn LD, Susman EJ, Pabst S, Huang B, Kalkwarf H, Grimes S. Association of depressive symptoms and anxiety with bone mass and density in ever-smoking and never-smoking adolescent girls. Arch Pediat Adolesc Med. 2008;162(12):1181-8.
13. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatry. 2010;71(3):e06.
14. Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int. 2008;19(1):1-12.
15. Pan HH, Li CY, Chen PC, et al. Contributions of diabetic macro-vascular complications and hip fracture to depression onset in elderly patients with diabetes: an 8-year population-based follow-up study. J Psychosom Res. 2012;73(3):180-4.
16. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38(4):213-24.
17. Sah R, Ekhator NN, Strawn JR, et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry. 2009;66(7):705-7.
18. Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem. 1992;59(1):73-80.
19. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452(7190):997-1001.
20. Crespi F. Influence of neuropeptide Y and antidepressants upon cerebral monoamines involved in depression: an in vivo electrochemical study. Brain Res. 2011;1407:27-37.
21. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13(7):803-11.
22. Baldock PA, Lee NJ, Driessler F, et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One. 2009;4(12):e8415.
23. Baldock PA, Sainsbury A, Allison S, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res. 2005;20(10):1851-7.
24. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109(7):915-21.
25. Lee NJ, Nguyen AD, Enriquez RF, et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone. 2011;48(3):461-7.
26. Hanson ES, Dallman MF. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol. 1995;7(4):273-9.
27. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry. 2004;9(4):326-57.
28. Allison SJ, Baldock P, Sainsbury A, et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem. 2006;281(33):23436-44.
29. Weinstein RS. Clinical practice: Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62-70.
30. Konno J, Yoshida S, Ina A, et al. Upregulated expression of neuropeptide Y in hypothalamic-pituitary system of rats by chronic dexamethasone administration. Neurosci Res. 2008;60(3):259-65.
31. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci. 1999;11(4):1431-48.
32. Nakashima A, Hayashi N, Kaneko YS, et al. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J Neural Transm. 2009;116(11):1355-62.
33. Dahlof P, Persson K, Lundberg JM, Dahlof C. Neuropeptide Y (NPY) induced inhibition of preganglionic nerve stimulation evoked release of adrenalin and noradrenaline in the pithed rat. Acta Physiol Scand. 1988;132(1):51-7.
34. Rasmusson AM, Southwick SM, Hauger RL, Charney DS. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Neuropsychopharmacology. 1998;19(1):95-8.
35. Mercer EH, Hoyle GW, Kapur RP, Brinster RL, Palmiter RD. The dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron. 1991;7(5):703-16.
36. Yirmiya R, Goshen I, Bajayo A, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S.A. 2006;103(45):16876-81.
37. Potter EK, Tripovic D. Modulation of sympathetic neurotransmission by neuropeptide Y Y2 receptors in rats and guinea pigs. Exp Brain Res. 2006;173(2):346-52.
38. Yang XP, Chiba S. Neuropeptide Y inhibits double peaked vasoconstrictor responses to periarterial nerve stimulation primarily through prejunctional Y2 receptor subtype in canine splenic arteries. Auton Autacoid Pharmacol. 2002;22(2):119-26.
39. Ma Y, Nyman JS, Tao H, Moss HH, Yang X, Elefteriou F. beta2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone. Endocrinology. 2011; 152(4):1412-22.
40. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res. 2004;57(4):353-8.
41. Tichomirowa MA, Keck ME, Schneider HJ, et al. Endocrine disturbances in depression. J Endocrinol Invest. 2005;28(1):89-99.
42. Wong ML, Kling MA, Munson PJ, et al. Pronounced, sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism,corticotropin-releasing hormone. Proc Natl Acad Sci U S.A. 2000;97(1):325-30.
43. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011;48(3):451-5.
44. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9(2):147-61.
45. Mickey BJ, Zhou Z, Heitzeg MM, et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry. 2011;68(2):158-66.
46. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. 1990;15(2):71-100.
47. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999;46(9):1167-80.
48. Dunn AJ, Swiergiel AH, Palamarchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann N Y Acad Sci. 2004;1018:25-34.
49. Suda T, Tozawa F, Dobashi I, et al. Corticotropin-releasing hormone, proopiomelanocortin, and glucocorticoid receptor gene expression in adrenocorticotropin-producing tumors in vitro. J Clin Invest. 1993;92(6):2790-5.
50. Thorsell A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Exp Biol Med (Maywood). 2010;235(10):1163-7.
51. Inoue W, Baimoukhametova DV, Fuzesi T, et al. Noradrenaline is a stress-associated metaplastic signal at GABA synapses. Nat Neurosci. 2013;16(5):605-12.
52. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008;473(2):231-6.
53. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514-20.
54. Pierroz DD, Bonnet N, Bianchi EN, et al. Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J Bone Miner Res. 2012;27(6):1252-62.
55. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305-17.